News & Events

• September 27, 2022
  

  Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation

  C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.

• September 8, 2022
  

  C-Path’s Kristen Swingle Named President

  Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
• June 30, 2022
  

  Diamyd Medical Joins International Consortium in Type 1 Diabetes

  Diamyd Medical will be a full voting member of the Type 1 Diabetes Consortium (T1DC) led by the US nonprofit organization Critical Path Institute (C-Path). The T1DC brings together diverse stakeholders from industry, academia and patient organizations to develop solutions to accelerate drug development for Type 1 Diabetes, including biomarker endpoints and model-informed drug development tools, in close collaboration with regulatory agencies to enable easier and faster regulatory approval of new treatments.

• June 2, 2022
  

  Biochemist, Biotechnology Expert to Lead C-Path’s Type 1 Diabetes Consortium

  C-Path has named Elnaz Atabakhsh, Ph.D., as Executive Director of its Type 1 Diabetes Consortium (T1DC). Atabakhsh joined C-Path this May with extensive experience in the biotechnology and biomarker development industry. Her previous work focused on biomarker discovery and screening, cancer genetics and cell therapies for autoimmune disorders, aimed at supporting patients unable to be served by traditional therapeutics. Atabakhsh has extensive experience in and a passion for leading patient-oriented, mission-driven collaborations that include diverse representation from the scientific and medical communities.

• April 5, 2022
  

  C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative

  TUCSON, Ariz., April 5, 2022 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium (T1DC) today announced that the European Medicines Agency (EMA) has issued a positive qualification opinion for pancreatic islet autoantibodies as enrichment biomarkers for type 1 diabetes (T1D) prevention trials. The purpose of this model-based qualification is to make publicly available tools...